dna friend

GenVec, Inc.: The Biggest Little Biotech

genvecerian. Let me know when you wish to compare apples to apples.
Genvec's current PACT TRIAL compares
TNFERADE + SOC VS .....SOC only....

The patients exclusions to participate in the SOC and TNFERADE + SOC are the same.. You can quote past statistics for Tarceva, but they are irrelevant for this study. But for my money, Tarceva is not worth the cost with the method of prescribing as of today. Few patients achieve stable disease by the time they are challenged with Tarceva.
Now relating to Genvec's TNFERADE. The current study recently had its endpoint changed per the FDA to OVERALL SURVIVAL, not six months, not one year... OVERALL SURVIVAL. its measured for both the SOC and TNFERADE + SOC. again apples to apples .

All patients in both arms are dealing only with nonresectable patients with stage 1,2,3 tumor burdens. Why not metastatic patients with stage four tumors. Because the survival rates are too low for that patient population and the ability to achieve statistical significance in that patient population would be null. That subset of patients can be tried once approval is gained. Genvec achieves nothing by attempting to cure STAGE 4 patients and attempting to treat them would cause significant financial drain on a company with limited resources.

How can you argue with a look at preliminary data that shows absolute survival at 71% TNF arm vs 28% SOC arm. in comparable patients populations.
Your conclusions lead me to believe you have a financial incentive to see the pact trial fail.